NCT05872256View on ClinicalTrials.gov

A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis

PHASE4CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

November 13, 2023

Study Completion Date

November 13, 2023

Conditions

Scalp Psoriasis

Interventions

DRUG

0.045% Tazarotene/0.01% Halobetasol Lotion

FDA approved drug for psoriasis treatment

Trial Locations (1)

27262

Dermatology Consulting Services, PLLC, High Point

Sponsors

Collaborators (1)

Ortho Dermatologics

All Listed Sponsors

collaborator

Ortho Dermatologics

INDUSTRY

lead

Dermatology Consulting Services, PLLC

NETWORK